In our latest HealthDay Now interview,Mabel Jong spoke to Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's new Alzheimer's drug. Dr. Alexander shared his thoughts on the drug's highly uncertain efficacy and discussed whether the FDA's reputation has been permanently damaged by the controversial approval of the drug.
Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.